Attovia grants 140,000 stock options to CBO
Attovia Therapeutics’ Chief Business Officer, Zaneta Odrowaz, received a grant of stock options for 140,000 shares of common stock on August 4, 2026.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Attovia Therapeutics’ Chief Business Officer, Zaneta Odrowaz, received a grant of stock options for 140,000 shares of common stock on August 4, 2026. The options carry a $17.00 per share exercise price and expire on August 3, 2036. 25% of the options vest on August 4, 2027, with the remaining options vesting in equal monthly installments over the following 36 months, subject to continued service. Following this award, she holds 140,000 stock options directly.
Insider Trade Summary
Grant/Award: 140,000 shares
Grant/Award
1 txn
Insider
Odrowaz Zaneta
Role
Chief Business Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 140,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 140,000 contracts (Direct)
Footnotes (1)
- F1. 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.
Key Figures
Stock options granted: 140,000 shares
Exercise price: $17.00 per share
Expiration date: August 3, 2036
+3 more
6 metrics
Stock options granted
140,000 shares
Options to buy Attovia Therapeutics common stock granted to Chief Business Officer
Exercise price
$17.00 per share
Conversion or exercise price of the granted stock options
Expiration date
August 3, 2036
Expiration date of the stock options granted on August 4, 2026
Initial cliff vesting
25% on August 4, 2027
Portion of options that vest one year after grant date
Remaining vesting period
36 months
Remaining options vest in equal monthly installments over 36 months
Options held after transaction
140,000 options
Total stock options directly held by Zaneta Odrowaz after the award
Key Terms
Stock Option (Right to Buy), exercise price, vesting, derivative securities, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 17.0000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"25% of the options shall vest on August 4, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
derivative securities financial
"reported as a grant or award acquisition of derivative securities"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
equal monthly installments financial
"remaining options shall vest in equal monthly installments"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity award did Attovia Therapeutics (ATTO) grant to its Chief Business Officer?
Attovia Therapeutics granted 140,000 stock options to Chief Business Officer Zaneta Odrowaz at an exercise price of $17.00 per share. These options provide the right to buy common stock if vesting and other conditions are met.
What is the vesting schedule for the 140,000 ATTO stock options granted to Zaneta Odrowaz?
The options vest 25% on August 4, 2027, with the remaining 75% vesting in equal monthly installments over the next 36 months. Vesting is conditioned on her continued service to Attovia Therapeutics through those dates.
What is the exercise price and expiration date of the new ATTO stock options?
The granted stock options have an exercise price of $17.00 per share and an expiration date of August 3, 2036. They allow purchase of Attovia Therapeutics common stock if exercised after vesting and before expiration.
How many Attovia Therapeutics stock options does Zaneta Odrowaz hold after this Form 4 transaction?
After this award, Zaneta Odrowaz holds 140,000 stock options directly. This reflects the full amount of the new grant, as disclosed, and represents options to purchase Attovia Therapeutics common stock upon future exercise.
Was the Attovia Therapeutics (ATTO) option grant to Zaneta Odrowaz made under a 10b5-1 trading plan?
The filing indicates the Rule 10b5-1 checkbox is not marked, and there is no footnote stating the grant is under a trading plan. The transaction is reported as a grant or award acquisition of derivative securities.
AI-generated analysis. How Rhea-AI works. Not financial advice.
